دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Effect of an Active vs Expectant Management Strategy on Successful Resolution of Pregnancy Among Patients With a Persisting Pregnancy of Unknown Location
Kurt T. Barnhart, MD1; Karl R. Hansen, MD2; Mary D. Stephenson, MD3; Rebecca Usadi, MD4; Anne Z. Steiner, MD5; Marcelle I. Cedars, MD6; Emily S. Jungheim, MD7; Kathleen M. Hoeger, MD8; Stephen A. Krawetz, PhD9; Benjie Mills, MD10; Meredith Alston, MD11; Christos Coutifaris, MD1; Suneeta Senapati, MD1; Sarita Sonalkar, MD1; Michael P. Diamond, MD12; Robert A. Wild, MD2; Mitchell Rosen, MD6; Mary D. Sammel, ScD13; Nanette Santoro, MD14; Esther Eisenberg, MD15; Hao Huang, MD16; Heping Zhang, PhD16; for the Reproductive Medicine Network
doi : 10.1001/jama.2021.10767
JAMA. 2021;326(5):390-400
Women with an early nonviable pregnancy of unknown location are at high risk of ectopic pregnancy and its inherent morbidity and mortality. Successful and timely resolution of the gestation, while minimizing unscheduled interventions, are important priorities.
Effect of a Sedation and Ventilator Liberation Protocol vs Usual Care on Duration of Invasive Mechanical Ventilation in Pediatric Intensive Care Units
Bronagh Blackwood, PhD1; Lyvonne N. Tume, PhD2,3; Kevin P. Morris, MD4,5; Mike Clarke, DPhil6; Clíona McDowell, MSc7; Karla Hemming, PhD8; Mark J. Peters, PhD9,10; Lisa McIlmurray, MPhil1; Joanne Jordan, DPhil1; Ashley Agus, PhD7; Margaret Murray, PhD7; Roger Parslow, PhD11; Timothy S. Walsh, MD12; Duncan Macrae, MB13; Christina Easter, MSc8; Richard G. Feltbower, PhD11; Daniel F. McAuley, MD1; for the SANDWICH Collaborators
doi : 10.1001/jama.2021.10296
JAMA. 2021;326(5):401-410
There is limited evidence on the optimal strategy for liberating infants and children from invasive mechanical ventilation in the pediatric intensive care unit.
Association of Dose Tapering With Overdose or Mental Health Crisis Among Patients Prescribed Long-term Opioids
Alicia Agnoli, MD, MPH, MHS1,2; Guibo Xing, PhD2; Daniel J. Tancredi, PhD2,3; Elizabeth Magnan, MD, PhD1,2; Anthony Jerant, MD1,2; Joshua J. Fenton, MD, MPH1,2,4
doi : 10.1001/jama.2021.11013
JAMA. 2021;326(5):411-419
Opioid-related mortality and national prescribing guidelines have led to tapering of doses among patients prescribed long-term opioid therapy for chronic pain. There is limited information about risks related to tapering, including overdose and mental health crisis.
Association Between Hospital Voluntary Participation, Mandatory Participation, or Nonparticipation in Bundled Payments and Medicare Episodic Spending for Hip and Knee Replacements
Joshua M. Liao, MD, MSc1; Atul Gupta, PhD2; Yueming Zhao, MPH3; Jingsan Zhu, MS3; Joseph Martinez, BS2; Deborah S. Cousins, MSPH3; Amol S. Navathe, MD, PhD3
doi : 10.1001/jama.2021.10046
JAMA. 2021;326(5):438-440
FDA Regulation and Approval of Medical Devices: 1976-2020
Jonathan J. Darrow, SJD, LLM, JD, MBA1; Jerry Avorn, MD1; Aaron S. Kesselheim, MD, JD, MPH1
doi : 10.1001/jama.2021.11171
JAMA. 2021;326(5):420-432
US law generally requires testing of high-risk medical devices prior to approval, as well as premarket evaluation of moderate-risk medical devices, with the goal of ensuring that the benefits of these products exceed their risks. The US Food and Drug Administration (FDA) attempts to balance the need for evidence generation with an approval process that facilitates access and encourages innovation.
Potential Benefits of Expanded COVID-19 Surveillance in the US
David R. Holtgrave, PhD1; Sten H. Vermund, MD, PhD2; Leana S. Wen, MD, MSc3
doi : 10.1001/jama.2021.11211
JAMA. 2021;326(5):381-382
Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval?
Kevin A. Schulman, MD1,2; Michael D. Greicius, MD, MPH3; Barak Richman, JD, PhD4
doi : 10.1001/jama.2021.11768
JAMA. 2021;326(5):383-384
Modernizing Public Health Data Systems
Kushal T. Kadakia, MSc1; Michael D. Howell, MD, MPH1; Karen B. DeSalvo, MD, MPH, MSc1
doi : 10.1001/jama.2021.12000
JAMA. 2021;326(5):385-386
Opioid Tapering Practices—Time for Reconsideration?
Marc Larochelle, MD1; Pooja A. Lagisetty, MD2,3; Amy S. B. Bohnert, PhD3,4
doi : 10.1001/jama.2021.11118
JAMA. 2021;326(5):388-389
Interpreting the Results of Intention-to-Treat, Per-Protocol, and As-Treated Analyses of Clinical Trials
Valerie A. Smith, DrPH1,2; Cynthia J. Coffman, PhD2,3; Michael G. Hudgens, PhD4
doi : 10.1001/jama.2021.2825
JAMA. 2021;326(5):433-434
Alopecia in a 36-Year-Old Man With HIV Infection
Maxime J. Billick, MDCM1; Wayne L. Gold, MD1,2
doi : 10.1001/jama.2021.7082
JAMA. 2021;326(5):435-436
Study Suggests Lasting Immunity After COVID-19, With a Big Boost From Vaccination
Jennifer Abbasi
doi : 10.1001/jama.2021.11717
JAMA. 2021;326(5):376-377
Evidence for a Colorectal Cancer Screening Benefit After Age 75 Years
Anita Slomski
doi : 10.1001/jama.2021.12115
JAMA. 2021;326(5):378
Ridesharing Services May Reduce Alcohol-Associated Car Crashes
Anita Slomski
doi : 10.1001/jama.2021.11306
JAMA. 2021;326(5):378
Is Dapagliflozin Cost-effective for Treating Heart Failure?
Anita Slomski
doi : 10.1001/jama.2021.12116
JAMA. 2021;326(5):378
Simple Intervention Motivates Expectant Fathers to Quit Smoking
Anita Slomski
doi : 10.1001/jama.2021.12117
JAMA. 2021;326(5):378
Collecting Patient-Reported Outcomes in Cancer Clinical Trials
Bridget M. Kuehn, MSJ
doi : 10.1001/jama.2021.12277
JAMA. 2021;326(5):379
FDA Approves Skin Graft Alternative for Thermal Burns
Bridget M. Kuehn, MSJ
doi : 10.1001/jama.2021.11703
JAMA. 2021;326(5):379
First Treatment for Plasminogen Deficiency Is Approved
Bridget M. Kuehn, MSJ
doi : 10.1001/jama.2021.12278
JAMA. 2021;326(5):379
Pain Management During Vaginal Childbirth
Jill Jin, MD, MPH1; Moeun Son, MD2
doi : 10.1001/jama.2021.10702
JAMA. 2021;326(5):450
The US Preventive Services Task Force Recommendation on Lung Cancer Screening
Bryan S. Squires, MD1; Ronald Levitin, MD1; Inga S. Grills, MD1
doi : 10.1001/jama.2021.8240
JAMA. 2021;326(5):440-441
The US Preventive Services Task Force Recommendation on Lung Cancer Screening—Reply
Michael J. Barry, MD1; Karina Davidson, PhD, MASc2; Carol M. Mangione, MD, MSPH3
doi : 10.1001/jama.2021.8243
JAMA. 2021;326(5):441
X-Waiver Exemption in the Treatment of Opioid Use Disorder
Riley D. Shearer, MSc1; Becky R. Ford, PhD2; Benjamin A. Howell, MD, MPH3
doi : 10.1001/jama.2021.8267
JAMA. 2021;326(5):441-442
X-Waiver Exemption in the Treatment of Opioid Use Disorder—Reply
Melissa B. Weimer, DO, MCR1; Sarah E. Wakeman, MD2; Richard Saitz, MD, MPH3
doi : 10.1001/jama.2021.8270
JAMA. 2021;326(5):442-443
